The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Wegovy was first to market but has been losing ground to Eli Lilly's Zepbound in recent months, according to the latest ...

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs ...

Novo is expanding its direct-to-consumer efforts around its obesity drug Wegovy, partnering with telehealth companies ...

Risinger also lowered Eli Lilly's price target from $989 to $944 on the formulary news, calling it a negative in a note Thursday. The deal with CVS is the latest this week as Novo Nordisk pushes ...

Eli Lilly told the firm it is not interested in exclusive "one-of-one" deals with PBMs, while Novo Nordisk said CVS approached the drugmaker about the Wegovy agreement, according to Seigerman.

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

PREMIUM Eli-Lilly-looks-set-to-steal-Novo-Nordisk-s-weight Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; Novo’s has ...